Nanoscope Therapeutics Propels Patient-Centered Innovation in Inherited Retinal Diseases with New Visionary Advisory Committee
DALLAS, June 26, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from ...
Nanoscope Director of Nonclinical Development, Dr. Subrata Batabyal, Recognized for Pioneering Work in Optogenetic Vision Restoration
Batabyal receives 2025 Carl Camras Translational Research Award from ARVO Foundation DALLAS, May 1, 2025 — Nanoscope Therapeutics Inc., a biotechnology company committed to restorin ...
Nanoscope Therapeutics Announces Participation at Eyecelerator® and ARVO 2025 Annual Meetings
Presentations to highlight efficacy, durability, and safety of Nanoscope's optogenetic therapy platforms DALLAS, April 25, 2025 -- Nanoscope Therapeutics Inc., a biotech company committed to ...
Pharmaceutical Industry Veteran, Ashish Patel, PhD, Joins Nanoscope as Senior Vice President of Sales and Marketing
DALLAS, March 27, 2025 -- Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerative diseases, today ...
Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
DALLAS, March 24, 2025 -- Researchers with Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing ...
Nanoscope Therapeutics Announces the Appointment of Ademola Daramola, D.Sc., as Vice President, Quality & Compliance
DALLAS, March 20, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene ther ...
Pharma Executive and Gene Therapy Access Expert, Ramesh Arjunji, PhD, Joins Nanoscope as Executive Vice President, Value and Access
DALLAS, March 5, 2025 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), t ...
Nanoscope Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Showcase
DALLAS, March 13, 2025 -- Nanoscope Therapeutics Inc., a biotech company committed to restoring vision in individuals who are blind or losing vision due to various retinal degenerati ...
Nanoscope Therapeutics to Present at the BIO CEO and Investor Conference
DALLAS, Feb. 6, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel g ...
Nanoscope Therapeutics Announces Presentations at Upcoming Medical Meetings
DALLAS, Feb. 4, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therap ...
Nanoscope Therapeutics to Present at the 21st Annual Advanced Therapies Week Conference
DALLAS, Jan. 20, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therap ...
Nanoscope Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
DALLAS, Jan. 9, 2025 -- Nanoscope Therapeutics Inc., a biotechnology company committed to restoring vision in blind patients in real-world settings by developing and commercializing novel gene therap ...
Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer
DALLAS, Dec. 5, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and geographic atrophy (GA), today announced t ...
Nanoscope’s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress
DALLAS, Dec. 2, 2024 — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) secondary to mac ...
Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia
DALLAS, Nov. 11, 2024 -- Nanoscope Therapeutics, Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), ...
Renowned Retinal Surgeon and Medical Entrepreneur, Sunil Gupta, MD, Joins Nanoscope Board of Directors
DALLAS Nov. 7, 2024 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today ...
Nanoscope Presented Positive 2-Year Randomized, Controlled Trial Results of MCO-010 for Retinitis Pigmentosa
DALLAS-Oct. 31, 2024 -- Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that positive 2-year results ...
Nanoscope Publishes Breakthrough Showing MCO-010 Treatment Arrests Neurodegeneration
DALLAS, Oct. 21, 2024 -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases today announced a breakthrough discovery ...
Nanoscope Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2024
DALLAS, Oct. 15, 2024 -- Nanoscope Therapeutics, Inc., a BLA filing-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that Nanoscope will present ...